MCP-1-deficiency decreased CD11c-expressing cells via impairing the production of ROS and decreased activation of PLCγ2, Akt, and ERK upon M-CSF stimulation in BMM. by Woon-Ki Kim (447798)

“…<p>BMMs from WT (open bar) and MCP-1-KO mice (oblique-lined bar) were incubated in the presence of M-CSF (30 ng/ml) with U73122 (10 µM), Akt inhibitor IV (0.3 µM), PD098059 (5 µM), DPI (50 nM), NAC (3 mM), or H₂O₂ (300 µM) for 4 d (A). *, <i>P</i><0.05; ***, <i>P</i><0.001 compared with vehicle-treated WT cells. …”

Enhanced thermal effect using magnetic nano-particles during high-intensity focused ultrasound by Surendra Balaji Devarakonda (3911542)

“…It was found that with the 0.047% mNP concentration, the power required to obtain a lesion volume of 13 mm³ can be halved, and the time required to achieve a 21 mm³ lesion decreased by a factor of 5. …”

Absorption spectra of 12.5 mM sodium chlorite solutions with different concentrations of sulfuric acid. by Ayuta Kishimoto (16814662)

Human adenovirus (HAdV) types HAdV-5 and HAdV-37 show decreased transduction efficiencies after treatment with cold atmospheric plasma (CAP). by Oskar Bunz (5900291)

Significant decrease of SMAD4 protein in DBA iPSCs. by Jingping Ge (636557)

“…A) Slight decrease of mRNA level of <i>SMAD4</i> in the DBA iPSCs with <i>RPS19</i> or <i>RPL5</i> mutations. …”

Decreased biomechanical stability of bones from <i>Col1a1-Krm2</i> transgenic mice. by Jochen Schulze (365258)

“…(D) Cortical thickness (C.Th.) and bone mineral density (vBMD) are decreased in <i>Col1a1-Krm2</i> transgenic mice compared to wildtype littermates. …”

Supplementary Material for: Decreasing Attacks and Improving Quality of Life through a Systematic Management Program for Patients with Hereditary Angioedema by Nunes F.L. (10223465)

sC5b-9 patients decrease in patients treated with mycophenolate mofetil. by Joshua M. Thurman (517193)

“…When analyzed separately based upon treatment, the decrease in sC5b-9 levels was due to a decrease in patients treated with mycophenolate mofetil (P < 0.001 by linear regression; n = 12 for all time-points). …”

The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial by Ma Somsouk (283498)

“…<div><p>The anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis. …”

Responding Vγ9Vδ2-individuals decreases among HIV-infected patients who present lower Vγ9Vδ2 T-cell number than HD. by Rita Casetti (608635)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)